Inmune Bio (INMB)
NASDAQ:INMB
Want to see INMB full AI Analyst Report?
Total Valuation
Inmune Bio has a market cap or net worth of $37.49M. The enterprise value is $18.43M.
Market Cap$37.49M
Enterprise Value$18.43M
Share Statistics
Inmune Bio has 26,585,258 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,585,258
Owned by Insiders11.17%
Owned by Institutions1.70%
Financial Efficiency
Inmune Bio’s return on equity (ROE) is -1.95 and return on invested capital (ROIC) is -125.70%.
Return on Equity (ROE)-1.95
Return on Assets (ROA)-1.42
Return on Invested Capital (ROIC)-125.70%
Return on Capital Employed (ROCE)-1.29
Revenue Per Employee3.85K
Profits Per Employee0.00
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inmune Bio is ―. Inmune Bio’s PEG ratio is 0.08.
PE Ratio―
PS Ratio829.46
PB Ratio1.76
Price to Fair Value1.76
Price to FCF-1.76
Price to Operating Cash Flow-2.00
PEG Ratio0.08
Income Statement
In the last 12 months, Inmune Bio had revenue of 50.00K and earned -45.93M in profits. Earnings per share was -1.86.
Revenue50.00K
Gross Profit50.00K
Operating Income-30.87M
Pretax Income-45.93M
Net Income-45.93M
EBITDA-30.79M
Earnings Per Share (EPS)-1.86
Cash Flow
In the last 12 months, operating cash flow was -19.17M and capital expenditures -1.60M, giving a free cash flow of -20.78M billion.
Operating Cash Flow-19.17M
Free Cash Flow-20.78M
Free Cash Flow per Share-0.78
Dividends & Yields
Inmune Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change-80.80%
50-Day Moving Average1.34
200-Day Moving Average1.68
Relative Strength Index (RSI)49.03
Average Volume (3m)411.44K
Important Dates
Inmune Bio upcoming earnings date is Aug 5, 2026, TBA (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Inmune Bio as a current ratio of 3.55, with Debt / Equity ratio of 7.69%
Current Ratio3.55
Quick Ratio3.55
Debt to Market Cap0.00
Net Debt to EBITDA0.77
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Inmune Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Inmune Bio EV to EBITDA ratio is -0.58, with an EV/FCF ratio of -0.75.
EV to Sales355.12
EV to EBITDA-0.58
EV to Free Cash Flow-0.75
EV to Operating Cash Flow-0.79
Balance Sheet
Inmune Bio has $21.36M in cash and marketable securities with $1.51M in debt, giving a net cash position of $19.85M billion.
Cash & Marketable Securities$21.36M
Total Debt$1.51M
Net Cash$19.85M
Net Cash Per Share$0.75
Tangible Book Value Per Share$0.88
Margins
Gross margin is 0.00%, with operating margin of -61738.00%, and net profit margin of -91866.00%.
Gross Margin0.00%
Operating Margin-61738.00%
Pretax Margin-91866.00%
Net Profit Margin-91866.00%
EBITDA Margin-61570.00%
EBIT Margin-61738.00%
Analyst Forecast
The average price target for Inmune Bio is $8.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.00
Price Target Upside422.88% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-100.00%
EPS Growth Forecast13.12%